Manufacturer
NOVARTIS PHARMA STEIN AG
Contents
Pasireotide
Indication
Cushing's disease
Instruction
Signifor is to be administered Subcutenous by self injection. Patients should receive instructions from the physician or a healthcare professional on how to inject Signifor SC.
Drug interaction
Increased risk of bradycardia with beta blockers (e.g. metoprolol); Ca channel blockers (e.g. verapamil); acetylcholinesterase inhibitors (e.g. physostigmine). May increase the risk QT prolongation with anti-arrhythmics (e.g. quinidine, amiodarone); antibacterials (e.g. clarithromycin, moxifloxacin); antipsychotics (e.g. chlorpromazine, haloperidol); antihistamines (e.g. terfenadine, astemizole); antimalarials (e.g. chloroquine, lumefantrine); antifungals (e.g. ketoconazole). May diminish therapeutic effects of ciclosporin. May increase serum concentration with bromocriptine
Malaysia
